BGLC · BioNexus Gene Lab Corp
$1.40
-0.07 (-4.76%)
At close · Sep 2
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.37M
Shares
2.93M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.